The B-cell Inhibitors Market stands as a vital sector within the biopharmaceutical industry, driven by escalating prevalence of autoimmune disorders including rheumatoid arthritis, lupus erythematosus, and multiple sclerosis. B-cell inhibitors represent a class of biological agents that specifically target B-cells—immune cells responsible for excessive immune activity in these...